About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Alzheimer's Disease Clinical Trials in Phoenix | 240 Studies

Clinical Trials Alzheimer's DiseasePhoenix

Alzheimer's Disease Clinical Trials in Phoenix

Find 240 clinical trials for alzheimer's disease near Phoenix, Arizona. Connect with research centers in your area.

All Alzheimer's Disease trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 41-60 of 240 trials

CompletedRosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's DiseaseRosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose.NCT00428090·Phoenix, Arizona and 137 others

Alzheimer's Disease Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedNuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's DiseaseThe primary objective of this study is to test the hypothesis that Nuedexta (20/10) administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity (CNS-Lability…NCT01832350·Phoenix, Arizona

Active not recruitingA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseThe purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to…NCT07170150·Phoenix, Arizona and 146 others

TerminatedStudy Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease PatientsThis is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease.NCT00676143·Birmingham, Alabama and 287 others

CompletedStudy Evaluating PAZ-417 in Healthy Young/ElderlyThis study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects.NCT00366288·Phoenix, Arizona

CompletedAutopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by…NCT01447719·Phoenix, Arizona and 21 others

CompletedTRC-PAD Program: In-Clinic Trial-Ready CohortThe purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials…NCT04004767·Birmingham, Alabama and 44 others

CompletedA Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®A study to assess the steady-state bioequivalence of once-weekly Corplex™ Donepezil 10 mg Transdermal Delivery System (TDS) compared to daily administration of Aricept®NCT03259958·Phoenix, Arizona

CompletedA Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseA phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.NCT04592874·Phoenix, Arizona and 86 others

TerminatedEfficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.NCT05602727·Phoenix, Arizona and 73 others

CompletedA Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's DiseaseThe objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the…NCT00322153·Phoenix, Arizona and 82 others

CompletedA Study of Semagacestat for Alzheimer's PatientsThe primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment.NCT01035138·Phoenix, Arizona and 70 others

RecruitingStudy to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseThis is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.NCT06808984·Homewood, Alabama and 77 others

Terminated221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseThe primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical…NCT02477800·Phoenix, Arizona and 180 others

TerminatedContinued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's DiseaseThis study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN…NCT01127633·Phoenix, Arizona and 146 others

TerminatedRandomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's DiseaseA multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's…NCT00021723·Peoria, Arizona and 10 others

Active not recruitingA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks.NCT05026866·Birmingham, Alabama and 215 others

CompletedSafety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.NCT00257673·Northport, Alabama and 56 others

TerminatedAn Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's DementiaThe purpose of this study is to evaluate whether treatment with atabecestat slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure…NCT02569398·Birmingham, Alabama and 127 others

TerminatedPhase 2 Study of BIIB092 in Participants With Early Alzheimer's DiseaseThe primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to…NCT03352557·Birmingham, Alabama and 100 others

PreviousPage 3 of 12Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia